查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1677169

暈動病治療市場按藥物類型、治療類型、劑型、通路和最終用戶分類 - 2025 年至 2030 年全球預測

Motion Sickness Treatment Market by Type Of Drugs, Treatment Type, Dosage Forms, Distribution Channel, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

暈動病治療市場預計在 2024 年達到 7.1969 億美元，2025 年達到 7.4093 億美元，到 2030 年將達到 8.6305 億美元，複合年成長率為 3.07%。

主要市場統計數據
基準年 2024 年 7.1969億美元
預計 2025 年 7.4093億美元
預測年份 2030 8.6305億美元
複合年成長率（%） 3.07%

暈動病長期以來一直是影響全球數百萬人的難題，其治療模式也發生了重大變化。本報告深入研究了不斷發展的行業，重點介紹了當前的治療方法和新興趨勢。隨著研究的進步和消費者偏好的變化，人們重新關注的不僅是緩解症狀，還增強患者的整體幸福感。

本介紹全面說明了創新治療方法、先進配方和獨特劑型如何重新定義患者照護。在平衡臨床準確性和市場洞察力的同時，後續內容深入探討產業轉型、分析細分洞察、區域市場動態和關鍵公司策略。每個部分都經過了細緻的研究，為行業領導者和決策者提供了清晰、可行的藍圖，以駕馭競爭格局。

該分析基於嚴格的資料收集、專家訪談和當代市場動態，為讀者提供了當前實踐和未來方向的整體概況。透過強調傳統治療方案和最新創新，該報告鼓勵相關人員考慮跨不同治療方法和分銷管道的綜合方法。透過這樣做，我們確保敘述不僅反映臨床效果，還反映市場可行性和患者便利性。

影響暈動病治療市場的不斷變化的趨勢

近年來，暈動病治療領域發生了重大變化。科技進步不僅增強了診斷能力和穿戴式感測設備，也促成了創新藥物輸送系統的出現。這種轉變正在推動市場從傳統的治療通訊協定轉向更客製化、高效和以患者為中心的方法。

最顯著的變化之一是數位健康技術的日益融合。數位治療和即時監測對於評估患者對各種治療方案的反應至關重要，從而可以實現更個人化的護理策略。藥理學的創新導致了改良劑型的開發，從而提高了吸收率並最大限度地減少了副作用。在這種動態的背景下，傳統治療方法正在被安全性和有效性顯著提高的現代治療方法所補充，在某些情況下甚至被取代。

另一個變革趨勢是消費行為的演變。知情的患者要求明確了解他們的治療方案，從而推動公司採用創新和前瞻性的策略。治療方法已發生明顯轉變，除了傳統的非處方藥和處方藥外，還採用自然療法。此外，市場進入策略擴大包括與科技公司建立策略合作夥伴關係，以開發應用程式和監控工具，擴大可獲得的治療見解和患者管理實踐的範圍。

這種不斷發展的格局的特點是科學突破與市場觀點的融合，並認知到綜合醫療保健解決方案的重要性。隨著從業者和投資者都在尋求永續成長的道路，該行業表現出臨床研究和市場主導創新之間的密切相互作用。從改進的配方到先進的交付管道，採用整體治療方法的動力凸顯了當今市場的變革性質。

正在進行的爭論不僅集中在個別治療方法的有效性上，還集中在新技術和創新經營模式將如何定義暈動病治療的未來。隨著監管機構簡化新產品和治療通訊協定的核准，該行業將迎來前所未有的合作、審查和市場滲透水平。

暈動病治療的全面細分見解

了解暈動病治療市場的重點是其複雜的細分。透過分析該行業，我們發現市場研究非常細緻，首先是根據藥品類型進行細分。本觀點將考慮抗膽鹼能藥物和抗組織胺藥物治療方法，強調每種藥物都提供了預防和緩解症狀的不同機制。這些化合物的細微動態不僅可以作為臨床實踐的指導，還可以作為未來研究和開發的指標。

此外，根據治療類型進行細分，市場分為自然療法、非處方藥和處方藥。這種區分至關重要，因為它反映了不同地區不同的患者需求和監管環境。自然療法由於其安全且沒有副作用而越來越受歡迎。另一方面，處方藥用於治療更嚴重的病例，需要在療效和安全性之間取得平衡。

分析將繼續關注劑型，分為注射劑、口服劑型和經皮吸收貼片。每種劑型都與特定的患者群體或臨床情況相關。注射劑通常用於治療急性症狀，而口服劑則方便定期使用。經皮貼片代表了一種現代藥物輸送方法，透過緩釋性機制提供穩定的治療水平，最大限度地提高療效，同時最大限度地減少血漿濃度波動。

另一層細分則著重於分銷管道，分為線上藥局和零售藥局。這種細分不僅反映了消費者購買行為的演變，也反映了數位轉型在製藥業日益成長的重要性。對數位平台的日益依賴凸顯了電子商務在覆蓋更廣泛的患者群體和及時有效地提供治療性介入的作用。

最後，根據診所、居家醫療、醫院等最終用戶進行的細分清楚地說明了市場的多面性。診所通常充當初步診斷和治療中心，而居家照護解決方案為慢性或不太嚴重的疾病提供便利。醫院表明需要進行重大而緊急的護理，並且通常採用更有條理的管理和監控方法。這些差異化細分市場提供的多層次洞察創建了一個對於策略規劃和市場定位至關重要的綜合框架。

了解這些細分策略不僅對市場負責人至關重要，而且對製藥創新者和臨床醫生也至關重要。每個部分雖然相互關聯，但都面臨著獨特的挑戰和機會，從而塑造了整體市場動態，確保治療環境能夠持續適應並回應患者需求和臨床進步。

目錄

第 1 章 簡介

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 人口老化加劇，出現暈動病症狀的風險較高
      • 運動引起的不適感在各年齡層的發生率都有增加
      • 全球旅行和旅遊趨勢的興起推動了對有效暈動病治療解決方案的需求。
    • 限制因素
      • 高昂的開發和製造成本影響了可負擔性和盈利
    • 機會
      • 與交通運輸和旅遊業合作，提供預防暈動病的解決方案
      • 透過基因和生物識別測試實施個人化醫療方法
    • 任務
      • 消費者對新治療方法療效的懷疑阻礙了其快速進入市場
  • 市場區隔分析
    • 藥物類型：抗膽鹼藥物對綜合暈動病管理和以患者為中心的護理策略的影響日益增強
    • 最終用戶：醫院在治療複雜暈動病病例方面發揮的作用越來越大，從而推動了醫療技術的先進。
  • 波特五力分析
  • PESTEL 分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第 6 章 暈動病治療市場（依治療類型）

  • 抗膽鹼能藥物
  • 抗組織胺藥

第 7 章 暈動病治療市場（依治療類型）

  • 自然療法
  • 非處方藥
  • 處方藥

第 8 章 暈動病治療市場（依劑型分類）

  • 注射
  • 口服
  • 經皮吸收貼片

第9章 暈動病治療市場（依通路）

  • 網路藥局
  • 零售藥局

第 10 章 暈動病治療市場（依最終使用者分類）

  • 診所
  • 居家護理
  • 醫院

第 11 章：美洲暈動病治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

12. 亞太地區暈動病治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

13. 歐洲、中東和非洲暈動病治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章 競爭格局

  • 2024 年市場佔有率分析
  • FPNV 定位矩陣，2024 年
  • 競爭情境分析
  • 戰略分析與建議

公司列表

  • Amneal Pharmaceuticals LLC
  • Astellas Pharma Inc.
  • Baxter International Inc.,
  • Bayer AG
  • BONINE by Wellspring Pharmaceutical Corporation
  • Cipla Limited
  • CVS Health Corporation
  • GlaxoSmithKline plc
  • Lupin Limited
  • Myungmoon Pharma Co. Ltd.
  • Novartis AG
  • Perrigo Company PLC
  • Pfizer Inc.
  • Prestige Consumer Healthcare Inc.,
  • Reliefband Technologies LLC
  • Sanofi SA
  • Taj Pharmaceuticals Limited
  • Teva Pharmaceutical Industries Limited
  • Torrent Pharmaceuticals Ltd
  • WellSpring Pharmaceutical Corporation
Product Code: MRR-A40F58415FBB

The Motion Sickness Treatment Market was valued at USD 719.69 million in 2024 and is projected to grow to USD 740.93 million in 2025, with a CAGR of 3.07%, reaching USD 863.05 million by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 719.69 million
Estimated Year [2025] USD 740.93 million
Forecast Year [2030] USD 863.05 million
CAGR (%) 3.07%

Motion sickness has long been a challenging condition affecting millions globally, and its treatment paradigm is undergoing significant change. The present report offers an in-depth look at the evolving industry, highlighting current therapeutic approaches and emerging trends. As research advances and consumer preferences shift, there is a renewed focus on not only alleviating symptoms but also enhancing overall patient well-being.

This introduction sets the stage for a comprehensive exploration of how innovative treatments, advanced drug formulations, and unique dosage forms are redefining patient care. With a balance of clinical precision and market insight, the content that follows delves into industry transformations, analytical segmentation insights, regional market dynamics, and key corporate strategies. Each segment is meticulously examined to provide industry leaders and decision-makers with a clear, actionable roadmap for navigating this competitive landscape.

This analysis is grounded in rigorous data collection, expert interviews, and contemporary market dynamics, ensuring that readers obtain a holistic overview of both current practices and future directions. By addressing both traditional treatment options and modern innovations, the report encourages stakeholders to consider integrative approaches that span various therapies and distribution channels. In doing so, it ensures that the narrative reflects not just clinical efficacy but also market viability and patient convenience.

Evolving Trends Shaping the Motion Sickness Treatment Market

In recent years, the treatment landscape for motion sickness has experienced transformative shifts. Technological advancements have not only enhanced diagnostic capabilities and wearable sensing devices but have also led to innovative drug delivery systems. These shifts have moved the market away from conventional treatment protocols towards approaches that are more tailored, efficient, and patient-centric.

One of the most notable changes is the increasing integration of digital health technology. Digital therapeutics and real-time monitoring have become integral in assessing patient response to various treatment options, enabling more personalized care strategies. Innovations in pharmacology have resulted in the development of enhanced dosage forms that improve absorption and minimize side effects. In this dynamic climate, conventional interventions are being supplemented-and in some cases replaced-by contemporary therapies that offer significant improvements in safety and efficacy.

Another transformative trend is the evolution in consumer behavior. Informed patients now demand clarity on treatment options, driving companies to innovate and adopt forward-thinking strategies. There is a notable shift towards therapies that embrace natural remedies alongside traditional over-the-counter and prescription medications. Furthermore, market strategies increasingly include strategic partnerships with tech firms to develop apps and monitoring tools, broadening the scope of accessible treatment insights and patient management practices.

This evolving landscape is characterized by a blend of scientific breakthroughs and a market perspective that recognizes the importance of integrated healthcare solutions. As practitioners and investors alike look for sustainable growth avenues, the sector is witnessing a robust interplay between clinical research and market-driven innovation. The drive to incorporate holistic approaches in treatment-encompassing everything from improved drug formulations to advanced delivery channels-underscores the transformative nature of the market today.

The ongoing discourse centers not merely on the efficacy of individual treatments but also on how emerging technologies and innovative business models can collectively define the future of motion sickness management. As regulatory bodies streamline the approval of new products and treatment protocols, the industry finds itself poised for unprecedented levels of collaboration, research, and market penetration.

Comprehensive Segmentation Insights in Motion Sickness Treatment

A critical aspect of understanding the motion sickness treatment market is its complex segmentation. Analysis of the industry reveals that market studies are conducted with considerable nuance, beginning with segmentation based on the type of drugs. This perspective examines treatments centered on anticholinergics and antihistamines, highlighting how each class offers distinct mechanisms for preventing and alleviating symptoms. The nuanced pharmacodynamics of these compounds serve not only as a guideline for clinical practice but also as a marker for future research developments.

Further segmentation exists through the prism of treatment type, where the market is divided among natural remedies, over-the-counter medications, and prescription medications. Such differentiation is crucial as it reflects varied patient needs and regulatory conditions across regions. Natural remedies have gained traction due to perceived safety and minimal side effects, whereas over-the-counter medications underscore accessibility and ease of use. Prescription medications, on the other hand, cater to more severe cases, requiring a balanced approach between potency and safety considerations.

The analysis continues by examining the dosage forms, which are segmented into injectable, oral, and transdermal patches. Each dosage form is associated with specific patient demographics and clinical scenarios. Injectable formulations often cater to acute episodes, while oral medications offer convenience for regular use. Transdermal patches, through sustained release mechanisms, offer the advantage of steady therapeutic levels, embodying a modern approach to drug delivery that maximizes efficacy while minimizing fluctuations in plasma concentration.

Another layer of segmentation focuses on the distribution channel, divided between online pharmacies and retail pharmacies. This segmentation not only reflects evolving consumer buying behaviors but also the growing importance of digital transformation in the pharmaceutical industry. The increasing trust in digital platforms underscores the role of e-commerce in reaching a broader patient base, enabling timely and efficient delivery of therapeutic interventions.

Lastly, segmentation based on the end user-including clinics, home care scenarios, and hospitals-provides a clear picture of the market's multi-dimensional nature. Clinics often serve as centers for initial diagnosis and treatment, while home care solutions offer convenience for chronic or less severe conditions. Hospitals, exemplifying the need for critical and immediate care, often adopt a more structured approach to administration and monitoring. The layered insights offered by these differentiated segments create a comprehensive framework that is critical for strategic planning and market positioning.

Understanding these segmentation strategies is essential not only for market strategists but also for pharmaceutical innovators and clinicians. Each segment, though interconnected, provides unique challenges and opportunities that shape the overall market dynamics, ensuring that the treatment landscape remains adaptable and responsive to both patient needs and clinical advancements.

Based on Type Of Drugs, market is studied across Anticholinergics and Antihistamines.

Based on Treatment Type, market is studied across Natural Remedies, Over-the-Counter Medications, and Prescription Medications.

Based on Dosage Forms, market is studied across Injectable, Oral, and Transdermal Patches.

Based on Distribution Channel, market is studied across Online Pharmacies and Retail Pharmacies.

Based on End User, market is studied across Clinics, Home Care, and Hospitals.

Regional Overview of Global Motion Sickness Treatment Markets

The regional dynamics of the motion sickness treatment market underscore significant variability and growth potential. Market insights indicate that the Americas, a region rich in advanced healthcare infrastructure, continue to be a leader in adopting new treatments and technologies. Here, rising awareness and a strong network of healthcare providers combine with an active pharmaceutical market, driving innovation and investment in both traditional and novel treatment methods.

In contrast, the Europe, Middle East & Africa region presents a unique mix of opportunities and challenges driven by differing regulatory landscapes and varying levels of technological adoption. Regulatory frameworks in Europe promote rigorous clinical testing and approval processes, ensuring that technological innovations meet high safety standards. Meanwhile, regions within the Middle East and Africa are witnessing increased investment in healthcare infrastructure, fostering an environment ripe for adopting advanced therapeutic approaches. Such variation necessitates adaptable strategies that cater to local market dynamics while aligning with global best practices.

The Asia-Pacific region, with its robust manufacturing capabilities and rapidly growing consumer base, is emerging as a critical market for motion sickness treatment. The region's dynamic growth is backed by a combination of traditional medical practices and modern pharmaceutical advancements. This dual approach is particularly beneficial in addressing both acute and chronic conditions of motion sickness, thereby contributing to a balanced market portfolio that spans from innovative drug formulations to traditional over-the-counter solutions.

Cross-regional analysis reveals that while each region faces its unique set of challenges-ranging from regulatory hurdles to cultural preferences-the overarching trends indicate an increasing harmonization of treatment protocols and market practices. Global connectivity has paved the way for shared innovations, with pharmaceutical research increasingly drawing on insights from diverse geographical areas. Such a synthesis of regional strengths not only enhances the overall quality of motion sickness treatment but also fosters an environment of collaboration between emerging and established markets.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Corporate Key Players Shaping the Motion Sickness Treatment Market

A review of key companies reveals a competitive environment where major players are driving change through innovation, strategic partnerships, and robust market positioning. Amneal Pharmaceuticals LLC and Astellas Pharma Inc. are renowned for their commitment to research and for offering effective anticholinergic and antihistaminic formulations that align with the unique needs of their patient bases. Baxter International Inc. and Bayer AG, with their extensive portfolio of over-the-counter products, have remained at the forefront of delivering accessible solutions that are widely trusted by consumers.

BONINE by Wellspring Pharmaceutical Corporation and Cipla Limited have further expanded the market by investing in advanced dosage forms and adopting rigorous quality control measures. CVS Health Corporation and GlaxoSmithKline plc have emerged as leaders in integrating digital health solutions into their distribution channels, thereby providing a seamless purchase experience for patients. Companies such as Lupin Limited and Myungmoon Pharma Co. Ltd. are recognized for their innovative approaches to prescription medications, offering alternatives that combine traditional pharmaceutical excellence with modern therapeutic benefits.

Novartis AG and Perrigo Company PLC are known for their targeted investments in research and development, focusing on the creation of new dosage forms like transdermal patches and sophisticated oral formulations that enhance patient compliance. Pfizer Inc. and Prestige Consumer Healthcare Inc. continue to leverage their global networks to drive market penetration, securing significant market shares through strategic collaborations. Reliefband Technologies LLC has carved a niche by introducing wearable solutions that complement pharmacological interventions, while Sanofi S.A. champions next-generation therapies that address the entire spectrum of motion sickness.

Taj Pharmaceuticals Limited, Teva Pharmaceutical Industries Limited, Torrent Pharmaceuticals Ltd, and WellSpring Pharmaceutical Corporation round out the list of key companies, each contributing uniquely to the dynamic market environment. Their combined efforts in research, innovation, and market expansion have fostered an ecosystem that nurtures continuous growth and resilience. These companies' commitment to clinical excellence and market adaptability underscores a broader industry trend focused on leveraging innovation to meet fluctuating consumer demands and stringent regulatory requirements.

Together, these industry leaders form a mosaic of expertise that spans global regions and a wide range of therapeutic needs. Their concerted efforts not only underscore the competitive spirit of the market but also highlight the collaborative potential that drives continuous improvement in motion sickness treatment.

The report delves into recent significant developments in the Motion Sickness Treatment Market, highlighting leading vendors and their innovative profiles. These include Amneal Pharmaceuticals LLC, Astellas Pharma Inc., Baxter International Inc.,, Bayer AG, BONINE by Wellspring Pharmaceutical Corporation, Cipla Limited, CVS Health Corporation, GlaxoSmithKline plc, Lupin Limited, Myungmoon Pharma Co. Ltd., Novartis AG, Perrigo Company PLC, Pfizer Inc., Prestige Consumer Healthcare Inc.,, Reliefband Technologies LLC, Sanofi S.A., Taj Pharmaceuticals Limited, Teva Pharmaceutical Industries Limited, Torrent Pharmaceuticals Ltd, and WellSpring Pharmaceutical Corporation. Strategic Recommendations for Advancing Motion Sickness Treatment Innovation

Industry leaders are encouraged to adopt a multi-faceted strategy to maintain competitive advantage and pioneer future innovations in motion sickness treatment. First, it is imperative to invest heavily in research and development to identify new therapeutic compounds that offer increased efficacy with reduced side effects. Strengthening R&D will catalyze the discovery of novel drug delivery systems-particularly in improving the bioavailability of both natural and synthetic remedies-thus ensuring treatments remain at the cutting edge of medical science.

Leveraging digital transformation is another key action point. Implementing advanced digital monitoring tools and integrating telemedicine solutions can greatly enhance patient management. Such digital strategies not only facilitate real-time data collection but also enable personalized treatment approaches that adjust to individual patient needs. As a result, companies can optimize therapy outcomes while ensuring a seamless patient experience.

Furthermore, fostering robust partnerships is essential. Collaborative efforts with technology companies, regulatory bodies, and academic institutions can unlock new insights that drive product innovation and market expansion. Strategic alliances can expedite the clinical trial processes and streamline regulatory approvals, offering companies a competitive edge in bringing next-generation therapies to market.

The importance of diversifying product portfolios cannot be overstated. Expanding offerings to include a range of dosage forms-such as injectables, oral medications, and transdermal patches-appears critical in catering to various clinical profiles and patient preferences. With an eye on market segmentation insights, companies should adapt their products to fit diverse distribution channels, whether via digital commerce or traditional retail pharmacies, enhancing overall market penetration.

Additionally, focusing on geographic diversification is recommended. Tailoring strategies to meet the unique regulatory and cultural needs of key regions such as the Americas, Europe, Middle East & Africa, and Asia-Pacific will help in maximizing market share. This might include localized clinical studies, region-specific marketing campaigns, and adaptations of product formulations to meet local consumer demands.

Lastly, industry leaders should continually monitor emerging trends and regulatory shifts. Staying abreast with global best practices and anticipating market disruptions through proactive policy alignment can provide significant strategic benefits. In an industry that is characterized by rapid innovation and stringent compliance requirements, a forward-thinking approach that marries clinical excellence with technological integration and strategic market positioning will prove indispensable.

Conclusion: Future Trajectories in Motion Sickness Treatment

Through rigorous analysis and detailed market segmentation, it becomes evident that the motion sickness treatment market is on the cusp of substantial evolution. The convergence of advanced pharmaceutical research, digital transformation, and strategic industry collaborations has created an environment ripe for innovative breakthroughs. Key insights reveal that from drug type classifications and treatment modality considerations to nuanced segmentation based on dosage forms, distribution channels, and end users, every facet of the market is interlinked with both clinical efficiency and market dynamics.

As treatment strategies are refined and tailored to specific patient needs, it is clear that future progress depends on a balanced approach that integrates both legacy therapies and modern innovations. The regional disparities and opportunities across the Americas, Europe, Middle East & Africa, and Asia-Pacific underscore the importance of a global perspective in developing comprehensive treatment protocols. Moreover, major industry players continue to push the envelope through rigorous R&D, strategic partnerships, and adaptive market strategies that cater to ever-evolving consumer demands.

This convergence of clinical rigor and market responsiveness is not only setting new benchmarks for treatment efficacy but is also reshaping the broader healthcare landscape. The continuous collaboration between researchers, healthcare providers, and industry leaders is essential for driving forward a new era of motion sickness management, one that is rooted in both scientific integrity and commercial dynamism. In essence, the motion sickness treatment landscape of tomorrow promises to be more integrated, patient-centric, and innovation-driven than ever before.

The insights summarized herein serve as a call for sustained investment, strategic foresight, and collaborative synergy, underscoring the need for stakeholders to not only respond to current trends but also anticipate future challenges. The future trajectory of this market, buoyed by technological and pharmaceutical innovations, signals robust growth and enhanced patient outcomes, marking an exciting era for all industry participants.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing aging population with a higher risk of developing motion sickness symptoms
      • 5.1.1.2. Rising prevalence of motion-induced discomfort among diverse age groups
      • 5.1.1.3. Growing global travel and tourism trends led to demand for effective motion sickness treatment solutions
    • 5.1.2. Restraints
      • 5.1.2.1. High development and manufacturing costs impacting affordability and profitability
    • 5.1.3. Opportunities
      • 5.1.3.1. Collaborating with transportation and tourism sectors to provide preventative motion sickness solutions
      • 5.1.3.2. Implementing personalized medicine approaches through genetic and biometric testing
    • 5.1.4. Challenges
      • 5.1.4.1. Consumer skepticism regarding the efficacy of emerging treatments hampers rapid market acceptance
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type Of Drugs: Rising impact of anticholinergics on comprehensive motion sickness management and patient-centric care strategies
    • 5.2.2. End User: Increasing role of hospitals in addressing complex motion sickness cases led to advanced medical technologies
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Motion Sickness Treatment Market, by Type Of Drugs

  • 6.1. Introduction
  • 6.2. Anticholinergics
  • 6.3. Antihistamines

7. Motion Sickness Treatment Market, by Treatment Type

  • 7.1. Introduction
  • 7.2. Natural Remedies
  • 7.3. Over-the-Counter Medications
  • 7.4. Prescription Medications

8. Motion Sickness Treatment Market, by Dosage Forms

  • 8.1. Introduction
  • 8.2. Injectable
  • 8.3. Oral
  • 8.4. Transdermal Patches

9. Motion Sickness Treatment Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Online Pharmacies
  • 9.3. Retail Pharmacies

10. Motion Sickness Treatment Market, by End User

  • 10.1. Introduction
  • 10.2. Clinics
  • 10.3. Home Care
  • 10.4. Hospitals

11. Americas Motion Sickness Treatment Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Motion Sickness Treatment Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Motion Sickness Treatment Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Amazon transforms healthcare delivery by integrating virtual consultations with upfront pay-per-visit pricing
    • 14.3.2. Panav Biotech launches FDA-approved Maropitine Injection to enhance pet care
    • 14.3.3. Zydus Lifesciences secures USFDA approval for its scopolamine transdermal system to transform motion sickness treatment
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Amneal Pharmaceuticals LLC
  • 2. Astellas Pharma Inc.
  • 3. Baxter International Inc.,
  • 4. Bayer AG
  • 5. BONINE by Wellspring Pharmaceutical Corporation
  • 6. Cipla Limited
  • 7. CVS Health Corporation
  • 8. GlaxoSmithKline plc
  • 9. Lupin Limited
  • 10. Myungmoon Pharma Co. Ltd.
  • 11. Novartis AG
  • 12. Perrigo Company PLC
  • 13. Pfizer Inc.
  • 14. Prestige Consumer Healthcare Inc.,
  • 15. Reliefband Technologies LLC
  • 16. Sanofi S.A.
  • 17. Taj Pharmaceuticals Limited
  • 18. Teva Pharmaceutical Industries Limited
  • 19. Torrent Pharmaceuticals Ltd
  • 20. WellSpring Pharmaceutical Corporation

LIST OF FIGURES

  • FIGURE 1. MOTION SICKNESS TREATMENT MARKET MULTI-CURRENCY
  • FIGURE 2. MOTION SICKNESS TREATMENT MARKET MULTI-LANGUAGE
  • FIGURE 3. MOTION SICKNESS TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 4. MOTION SICKNESS TREATMENT MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS MOTION SICKNESS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 19. AMERICAS MOTION SICKNESS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES MOTION SICKNESS TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 21. UNITED STATES MOTION SICKNESS TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC MOTION SICKNESS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC MOTION SICKNESS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA MOTION SICKNESS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA MOTION SICKNESS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. MOTION SICKNESS TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 27. MOTION SICKNESS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. MOTION SICKNESS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. MOTION SICKNESS TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY NATURAL REMEDIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY OVER-THE-COUNTER MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY PRESCRIPTION MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY TRANSDERMAL PATCHES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL MOTION SICKNESS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS MOTION SICKNESS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES MOTION SICKNESS TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC MOTION SICKNESS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 68. CHINA MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 73. INDIA MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 78. INDONESIA MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 83. JAPAN MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 88. MALAYSIA MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 93. PHILIPPINES MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 94. PHILIPPINES MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 98. SINGAPORE MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 99. SINGAPORE MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 103. SOUTH KOREA MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 104. SOUTH KOREA MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 108. TAIWAN MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 109. TAIWAN MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 113. THAILAND MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 114. THAILAND MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 118. VIETNAM MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 119. VIETNAM MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA MOTION SICKNESS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 129. DENMARK MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 130. DENMARK MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 134. EGYPT MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 135. EGYPT MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 139. FINLAND MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 140. FINLAND MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 144. FRANCE MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 145. FRANCE MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 149. GERMANY MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 150. GERMANY MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 154. ISRAEL MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 159. ITALY MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 164. NETHERLANDS MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 169. NIGERIA MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 174. NORWAY MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 175. NORWAY MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 179. POLAND MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 180. POLAND MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 184. QATAR MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 185. QATAR MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 189. RUSSIA MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 190. RUSSIA MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 194. SAUDI ARABIA MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH AFRICA MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH AFRICA MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 204. SPAIN MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 205. SPAIN MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 209. SWEDEN MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 210. SWEDEN MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 214. SWITZERLAND MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 215. SWITZERLAND MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 219. TURKEY MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 220. TURKEY MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 224. UNITED ARAB EMIRATES MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED KINGDOM MOTION SICKNESS TREATMENT MARKET SIZE, BY TYPE OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED KINGDOM MOTION SICKNESS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM MOTION SICKNESS TREATMENT MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM MOTION SICKNESS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM MOTION SICKNESS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 234. MOTION SICKNESS TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 235. MOTION SICKNESS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024